<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540591</url>
  </required_header>
  <id_info>
    <org_study_id>22012</org_study_id>
    <nct_id>NCT01540591</nct_id>
  </id_info>
  <brief_title>Intralipid for Repeated Implantation Failure</brief_title>
  <acronym>Intralipid</acronym>
  <official_title>Does Intralipid Infusion Improve the Implantation Rate in Repeated Implantation Failure: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intralipid infusion can improve outcome in women with recurrent Intracytoplasmic sperm
      injection ( ICSI) failure due to elevated TH1 cytokine response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infertile patients undergoing Intracytoplasmic Sperm Injection (ICSI) cycle with history of
      repeated implantation failure, intralipid will be given to the intervention group.

      The primary outcome measure is the clinical pregnancy rate, secondary outcome measures
      implantation rate, ongoing pregnancy rate, abortion rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>10 month</time_frame>
    <description>pregancy sac with fetal heart activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>10 month</time_frame>
    <description>the number of gestational sacs divided by the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>14 month</time_frame>
    <description>clinical pregnancy continue after 12 weeks gestational age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 0.9% IV infusion between day 4 and 9 of ovarian stimulation &amp; another dose when got pregnant within the 1st week of positive pregnancy test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intralipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation &amp; another dose when got pregnant within the 1st week of positive pregnancy test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intralipid</intervention_name>
    <description>IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation &amp; another dose when got pregnant within the 1st week of positive pregnancy test</description>
    <arm_group_label>intralipid</arm_group_label>
    <other_name>intralipid 20%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation &amp; another dose when got pregnant within the 1st week of positive pregnancy test</description>
    <arm_group_label>control</arm_group_label>
    <other_name>Saline 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infertile patients undergoing ICSI cycle with history of repeated implantation failure

        Exclusion Criteria:

          1. Disturbances of normal fat metabolism such as pathologic hyperlipemia

          2. Allergic to it; or to eggs, soybean oil, or safflower oil.

          3. Severe liver disease, kidney disease, lung disease, anemia, blood clotting disorder.

          4. Uterine fibroid, endometrial polyp, endometriosis and hydrosalpinx.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waleed El-khayat, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine, Cairo University, Cairo, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr Al-ainy hospital</name>
      <address>
        <city>Cairo</city>
        <zip>12211</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Waleed El-khayat</investigator_full_name>
    <investigator_title>Assisstant professor</investigator_title>
  </responsible_party>
  <keyword>repeated implantation failure</keyword>
  <keyword>intralipid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

